A Double-blind, Randomized, Placebo-controlled, Phase I , Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease.
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2012
At a glance
- Drugs HPP 854 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 29 Aug 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 29 May 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.